

August 4, 2021

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma Listed Continuously in FTSE4Good Index Series and FTSE Blossom Japan Index of ESG Indices**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura) announced today that it has been selected for inclusion in the FTSE4Good Index Series, global stock indices for Environmental, Social, and Governance (ESG), for 19 years in succession, starting in 2003, and in FTSE Blossom Japan Index Series, which was launched in 2017, for 5 years in succession.

The FTSE4Good Index Series is designed by FTSE Russell\* to measure the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices. Transparent management and clearly-defined ESG criteria make FTSE4Good indexes suitable tools to be used by a wide variety of market participants when creating or assessing sustainable investment products.

The FTSE Blossom Japan Index is created by FTSE Russell to measure the performance of Japanese companies with excellent responses to ESG issues.



FTSE4Good

FTSE Blossom  
Japan

Along with being listed in the FTSE4Good Index Series and the FTSE Blossom Japan Index, Sumitomo Dainippon Pharma also has been selected for the MSCI Japan ESG Select Leaders Index for 5 years in succession and the MSCI Japan Empowering Women Index (WIN) for 3 years in succession, which are the ESG investment indices selected by the Government Pension Investment Fund (GPIF).

Corporate Mission of Sumitomo Dainippon Pharma is "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". Sumitomo Dainippon Pharma defines the implementation of this Corporate Mission as "CSR-Based Management". Sumitomo Dainippon Pharma will continue to promote CSR-based management and aim at the sustained enhancement of corporate value.

\* FTSE Russell: A company that delivers tools for investment decision-making on a global scale, including the development and management of numerous indices. Wholly owned by the London Stock Exchange.

**Reference**

For Initiatives of CSR-based management and sustainability of Sumitomo Dainippon Pharma and external evaluation, please visit: <https://www.ds-pharma.com/csr/>

**Contact:**

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)